Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Harvard Business School
Dow
Mallinckrodt
Baxter

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LY2140023

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for LY2140023?

LY2140023 is an investigational drug.

There have been 23 clinical trials for LY2140023. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.

The most common disease conditions in clinical trials are Schizophrenia, Stress Disorders, Traumatic, and Stress Disorders, Post-Traumatic. The leading clinical trial sponsors are Eli Lilly and Company, New York State Psychiatric Institute, and National Institute of Mental Health (NIMH).

There are five US patents protecting this investigational drug and seventy-two international patents.

Recent Clinical Trials for LY2140023
TitleSponsorPhase
Glutamate Reducing Interventions in SchizophreniaNational Institute of Mental Health (NIMH)Phase 1
Glutamate Reducing Interventions in SchizophreniaNew York State Psychiatric InstitutePhase 1
Pomaglumetad Effects on Glutamate BiomarkersNational Institute of Mental Health (NIMH)Phase 1

See all LY2140023 clinical trials

Clinical Trial Summary for LY2140023

Top disease conditions for LY2140023
Top clinical trial sponsors for LY2140023

See all LY2140023 clinical trials

US Patents for LY2140023

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY2140023   Start Trial Prodrugs of excitatory amino acids Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2140023   Start Trial Prodrugs of excitatory amino acids Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2140023   Start Trial Methods of treatment using a prodrug of an excitatory amino acid Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2140023   Start Trial Methods of treatment using a prodrug of an excitatory amino acid Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY2140023

Drugname Country Document Number Estimated Expiration Related US Patent
LY2140023 Argentina 040257 2022-06-11   Start Trial
LY2140023 Austria 421526 2022-06-11   Start Trial
LY2140023 Austria 438354 2022-06-11   Start Trial
LY2140023 Australia 2003232146 2022-06-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.